Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.

作者: Mylene T. Truong , Edith M. Marom , Jeremy J. Erasmus

DOI: 10.1097/00005382-200605000-00006

关键词:

摘要: Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis poor with a median survival 8 to 18 months after diagnosis. Multimodality regimens combining chemotherapy, radiotherapy, immunotherapy, and surgery are being used more frequently in patient management. Extrapleural pneumonectomy surgical treatment choice 10% 15% patients who present resectable disease reported prolong survival. Accurate staging important distinguish those requiring palliative therapy. Integrated computed tomography-positron emission tomography (CT-PET) increases accuracy overall MPM significantly improves selection for curative resection. Specifically, CT-PET detects extensive involvement than that shown by other imaging modalities particularly useful identifying occult distant metastases. This article reviews aspects performed initial according International Mesothelioma Interest Group system will emphasize appropriate role determining T, N, M descriptors.

参考文章(37)
Anna K. Nowak, Richard A. Lake, Hedy Lee Kindler, Bruce W.S. Robinson, New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Seminars in Oncology. ,vol. 29, pp. 82- 96 ,(2002) , 10.1053/SONC.2002.30234
Hedy Lee Kindler, Malignant pleural mesothelioma. Current Treatment Options in Oncology. ,vol. 1, pp. 313- 326 ,(2000) , 10.1007/S11864-000-0047-4
Raja M Flores, Timothy Akhurst, Mithat Gonen, Steven M Larson, Valerie W Rusch, Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 126, pp. 11- 15 ,(2003) , 10.1016/S0022-5223(03)00207-1
Cristina Nanni, Paolo Castellucci, Mohsen Farsad, Carmine Pinto, Andrea Moretti, Cinzia Pettinato, Mario Marengo, Stefano Boschi, Roberto Franchi, Andrea Martoni, Nino Monetti, Stefano Fanti, Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biotherapy and Radiopharmaceuticals. ,vol. 19, pp. 149- 154 ,(2004) , 10.1089/108497804323071913
Derlis Martino, Harvey I. Pass, Integration of Multimodality Approaches in the Management of Malignant Pleural Mesothelioma Clinical Lung Cancer. ,vol. 5, pp. 290- 298 ,(2004) , 10.3816/CLC.2004.N.008
Edith M. Marom, Jeremy J. Erasmus, Harvey I. Pass, Edward F. Patz, The role of imaging in malignant pleural mesothelioma. Seminars in Oncology. ,vol. 29, pp. 26- 35 ,(2002) , 10.1053/SONC.2002.30228
Stephen G. Swisher, Jack A. Roth, p53 Gene therapy for lung cancer Current Oncology Reports. ,vol. 4, pp. 334- 340 ,(2002) , 10.1007/S11912-002-0009-Z
Darren B. Schneider, Carolyn Clary-Macy, Sudha Challa, Kent C. Sasse, Scott H. Merrick, Randall Hawkins, Gary Caputo, David Jablons, Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 120, pp. 128- 133 ,(2000) , 10.1067/MTC.2000.106529
Jeremy J. Erasmus, Mylene T. Truong, W. Roy Smythe, Reginald F. Munden, Edith M. Marom, David C. Rice, Ara A. Vaporciyan, Garrett L. Walsh, Bradley S. Sabloff, Lyle D. Broemeling, Craig W. Stevens, Katherine M. Pisters, Donald A. Podoloff, Homer A. Macapinlac, Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 129, pp. 1364- 1370 ,(2005) , 10.1016/J.JTCVS.2004.10.034
François Bénard, Daniel Sterman, Robin J. Smith, Larry R. Kaiser, Steven M. Albelda, Abass Alavi, Metabolic Imaging of Malignant Pleural Mesothelioma With Fluorodeoxyglucose Positron Emission Tomography Chest. ,vol. 114, pp. 713- 722 ,(1998) , 10.1378/CHEST.114.3.713